Skip to main content

Event Details
Full Schedule
Posters
Speakers
Presidential Trainees
Partners & Opportunities
Awardees
Career Center
ASCPT Volunteer Survey

ASCPT 2024 Annual Meeting Main banner

+Event Details
+Full Schedule
+Posters
Speakers
Presidential Trainees
Partners & Opportunities
Awardees
Career Center
ASCPT Volunteer Survey

Browse by Poster Title

Home
Browse by Poster Title

Browse by Poster Title

326 results found

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

A
PII-035
A BIOEQUIVALENCE AND FOOD EFFECT CLINICAL STUDY OF ZOLIFLODACIN, FIRST-IN-CLASS ORAL ANTIBIOTIC, BEING DEVELOPED FOR THE TREATMENT OF UNCOMPLICATED GONORRHEA

Favorite
PII-210
A BIOMARKER-FOCUSED QSP MODEL OF COMPLEMENT ALTERNATIVE AND TERMINAL PATHWAYS TO EVALUATE POTENTIAL TARGETS FOR THERAPEUTIC IMPACT IN COMPLEMENT-ASSOCIATED DISEASES: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) AS A CASE STUDY.

Favorite
PII-041
A CHEMICAL BIOLOGY STRATEGY FOR PREDICTING OATP1B-TYPE TRANSPORTER-MEDIATED DRUG-DRUG INTERACTION (DDI) LIABILITIES

Favorite
TIP-001
A CLINICAL STUDY OF NOVEL BCRP AND ESTABLISHED OATP BIOMARKERS FOR PREDICTING DRUG-DRUG INTERACTIONS.

Favorite
PII-179
A COMPUTATIONAL TOOL TO OPTIMIZE CLINICAL TRIAL DESIGN FOR DUCHENNE MUSCULAR DYSTROPHY: A PRACTICAL GUIDE AND CASE STUDIES.

Favorite
LB-001
A GENERIC TACROLIMUS CAPSULE SHOWN NOT TO BE BIOEQUIVALENT TO THE BRAND TACROLIMUS CAPSULE IN A POST-APPROVAL PHARMACOKINETIC BIOEQUIVALENCE STUDY IN HEALTHY SUBJECTS

Favorite
PT-006
A GENOME-WIDE DNA METHYLATION ANALYSIS REVEALS DIFFERENT METHYLATION PATTERNS AND MECHANISTIC CLUES OF MEDICATION-RELATED OSTEONECROSIS OF THE JAW.

Favorite
OAII-003
A LONGITUDINAL HBA1C MODEL IN PATIENTS WITH TYPE 2 DIABETES ELUCIDATES THE ROLE OF CODING VARIANT IN GLUCOSE TRANSPORTER GENE, SLC2A2, ON GLYCEMIC RESPONSE TO METFORMIN.

Favorite
PT-003
A LONGITUDINAL HBA1C MODEL IN PATIENTS WITH TYPE 2 DIABETES ELUCIDATES THE ROLE OF CODING VARIANT IN GLUCOSE TRANSPORTER GENE, SLC2A2, ON GLYCEMIC RESPONSE TO METFORMIN.

Favorite
LB-002
A MINIMAL PHYSIOLOGICALLY BASED PHARMACOKINETIC (MPBPK) MODEL TO CHARACTERIZE PSA07 BACTERIOPHAGE (PHAGE) PHARMACOKINETICS (PK) FOLLOWING INTRAVENOUS (IV) ADMINISTRATION IN MICE FOR TREATMENT OF P. AERUGINOSA (PSA) INFECTIONS

Favorite
PII-005
A NOVEL ENDOTYPE OF ADULT ASTHMA SUGGESTED BY PLASMA METABOLITE PROFILING OF THE COHORT FOR REALITY AND EVOLUTION OF ADULT ASTHMA IN KOREA (COREA)

Favorite
LB-003
A NOVEL MECHANISTIC PHYSIOLOGICALLY BASED PHARMACOKINETIC-PHARMACODYNAMIC (PBPK-PD) MODEL TO ASSESS DRUG-DRUG INTERACTION (DDI) RISKS FOR ACID REDUCING AGENTS (ARA).

Favorite
LB-004
A NOVEL PHYSIOLOGICALLY BASED OCULAR PHARMACOKINETIC MODEL INCORPORATING ACCURATE DYNAMICS OF THE ANTERIOR EYE

Favorite
PII-090
A PHARMACOKINETIC AND ENZYME TURNOVER MODEL PREDICTS MAJOR ROLES FOR CYP2B6 GENOTYPES ON THE MAGNITUDE OF EFAVIREZ AUTOINDUCTION OF METABOLISM AND CLEARNCE IN HEALTHY VOLUNTEERS

Favorite
LB-005
A PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF AMX0035 IN PARTICIPANTS WITH AMYOTROPHIC LATERAL SCLEROSIS

Favorite
PII-091
A PHASE 1 OPEN-LABEL, FIXED-SEQUENCE 3-PERIOD STUDY TO EVALUATE PHARMACOKINETIC INTERACTIONS BETWEEN FIMASARTAN AND INDAPAMIDE IN HEALTHY VOLUNTEERS

Favorite
PII-092
A PHASE 1 SINGLE ASCENDING DOSE (SAD) STUDY OF FOOD EFFECTS AND DRUG-DRUG INTERACTION (DDI) EFFECTS OF PH-MODIFYING AGENTS ON INCB099318 PHARMACOKINETICS (PK), A PROGRAMMED DEATH-LIGAND 1 (PD-L1) INHIBITOR, IN HEALTHY PARTICIPANTS

Favorite
PII-194
A PHASE 1 STUDY COMPARING PHARMACOKINETICS OF RIMEGEPANT 25 MG ORALLY DISINTEGRATING TABLET (ODT) PEDIATRIC FORMULATION WITH RIMEGEPANT 75 MG ODT ADULT FORMULATION, WHEN ADMINISTERED AT A SINGLE DOSE OF 75 MG UNDER FASTING CONDITIONS

Favorite
PII-195
A PHASE 1 STUDY OF THE PHARMACOKINETICS OF ADAGRASIB IN SUBJECTS WITH MILD, MODERATE, OR SEVERE HEPATIC IMPAIRMENT COMPARED TO SUBJECTS WITH NORMAL HEPATIC FUNCTION.

Favorite
PII-196
A PHASE 1 STUDY OF THE PHARMACOKINETICS OF ADAGRASIB IN SUBJECTS WITH MILD, MODERATE, OR SEVERE RENAL IMPAIRMENT COMPARED TO SUBJECTS WITH NORMAL RENAL FUNCTION.

Favorite
PII-093
A PHASE 1, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS OF A SINGLE DOSE OF DAZODALIBEP IN HEALTHY JAPANESE AND CAUCASIAN PARTICIPANTS.

Favorite
PII-094
A PHASE 1, SINGLE ASCENDING DOSE (SAD) STUDY OF FOOD EFFECT AND DRUG-DRUG INTERACTION (DDI) EFFECTS OF PH-MODIFYING AGENTS ON INCB099280 PHARMACOKINETICS (PK), A PROGRAMMED DEATH-LIGAND 1 (PD-L1) INHIBITOR, IN HEALTHY PARTICIPANTS

Favorite
PII-095
A POPULATION PHARMACOKINETIC (PK) MODEL OF MILVEXIAN, A SMALL MOLECULE FACTOR XIA INHIBITOR, IN HEALTHY VOLUNTEERS.

Favorite
PII-185
A QUANTITATIVE MODELING APPROACH TO PREDICT AVAILABILITY OF GENERIC ORPHAN DRUG PRODUCTS.

Favorite
PII-211
A QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) MODEL FOR PRECLINICAL TO CLINICAL TRANSLATION OF ANTIBODY-DRUG CONJUGATE (ADC) EFFICACY AND THROMBOCYTOPENIA.

Favorite
PII-212
A QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) MODEL FOR PREDICTING EFFICACY FOR A COMBINATION OF AN ANTIBODY DRUG CONJUGATE (ADC) AND A CHECKPOINT INHIBITOR (CPI) IN PHASE II/III CLINICAL TRIALS

Favorite
PII-006
A SNAPSHOT OF PHARMACODYNAMIC BIOMARKERS BIOANALYSIS IN 16 BLAS APPROVED FOR NEUROLOGY INDICATIONS.

Favorite
PII-186
A SURVEY ON RECOMMENDATION OF FOOD CONDITIONS IN BIOEQUIVALENCE STUDIES WITH PHARMACOKINETIC ENDPOINTS FOR GENERIC ORAL ANTINEOPLASTIC DRUG DEVELOPMENT.

Favorite
PWI-002
A TRANSLATIONAL MODELING AND SIMULATION APPROACH TO INFORM FIRST-IN-HUMAN DOSE SELECTION FOR AN SIRNA TARGETING COMPLEMENT C3.

Favorite
PII-096
A TRANSLATIONAL MODELING AND SIMULATION APPROACH TO INFORM FIRST-IN-HUMAN DOSE SELECTION FOR AN SIRNA TARGETING COMPLEMENT C3.

Favorite
PII-072
A VALUE PROPOSITION FOR USING PHARMACOGENETIC TESTING IN MENTAL HEALTH CARE

Favorite
PII-045
ACETYLATION-DEPENDENT REGULATION OF NUCLEAR PD-L1 IS CRITICAL TO SISTER CHROMATID COHESION IN TRIPLE NEGATIVE BREAST CANCER

Favorite
CT-009
ADDRESSING THE RACIAL DISPARITY OF ANGIOTENSIN INHIBITOR ASSOCIATED REDUCTION IN HFREF HOSPITALIZATIONS: DISTINGUISHING BETWEEN RACE AND ANCESTRY

Favorite
PII-073
ADDRESSING THE RACIAL DISPARITY OF ANGIOTENSIN INHIBITOR ASSOCIATED REDUCTION IN HFREF HOSPITALIZATIONS: DISTINGUISHING BETWEEN RACE AND ANCESTRY

Favorite
CT-001
AGE-APPROPRIATE DOSING FOR DEXAMETHASONE TO PREVENT POST-EXTUBATION STRIDOR: A PEDIATRIC PBPK MODELING APPROACH

Favorite
PII-160
AGE-APPROPRIATE DOSING FOR DEXAMETHASONE TO PREVENT POST-EXTUBATION STRIDOR: A PEDIATRIC PBPK MODELING APPROACH

Favorite
OAII-002
ALCOHOL USE DISORDER PHARMACOGENOMICS: ROLE OF FNDC4 IN HUMAN NEURONAL FUNCTION.

Favorite
PT-010
ALCOHOL USE DISORDER PHARMACOGENOMICS: ROLE OF FNDC4 IN HUMAN NEURONAL FUNCTION.

Favorite
PII-046
AN EVALUATION OF THE DRUG INTERACTION POTENTIAL OF ENCORAFENIB IN COMBINATION WITH BINIMETINIB USING THE INJE COCKTAIL IN PATIENTS WITH BRAF V600-MUTANT UNRESECTABLE OR METASTATIC MELANOMA OR OTHER ADVANCED SOLID TUMORS

Favorite
PII-097
AN INTEGRATED ASSESSMENT OF THE AME PROPERTIES OF SELTOREXANT UTILIZING PRECLINICAL IN VITRO, IN VIVO, AND HUMAN ADME DATA.

Favorite
PII-047
AN OPEN-LABEL BIOEQUIVALENCE STUDY IN HEALTHY VOLUNTEERS TO COMPARE THE PHARMACOKINETICS OF TWO DIFFERENT TABLET STRENGTHS OF SOTORASIB IN THE FED AND FASTED STATE

Favorite
PII-043
ANTIDEPRESSANT EXPOSURE IN THE ADOLESCENT BRAIN: FLUOXETINE AND PHARMACOGENETIC INFLUENCES ON BRAIN DISPOSITION

Favorite
PII-048
APPARENT FCRN DYSFUNCTION IN CANCER CACHEXIA DECREASES EXTRAVASCULAR IMMUNOGLOBULIN G ABSORPTION.

Favorite
AI-001
APPLICATION OF GAUSSIAN PROCESS MODEL IN LONGITUDINAL PHARMACOKINETIC/PHARMACODYNAMIC DATA AND COMPARISON WITH NATURAL LANGUAGE PROCESSING MODELS

Favorite
PII-098
APPLICATION OF GAUSSIAN PROCESS MODEL IN LONGITUDINAL PHARMACOKINETIC/PHARMACODYNAMIC DATA AND COMPARISON WITH NATURAL LANGUAGE PROCESSING MODELS

Favorite
AI-002
APPLICATION OF MACHINE LEARNING COMBINED WITH POPPK AND QSP MODELS FOR ADVERSE EVENTS RISK PREDICTION OF A CD19-TARGETING BISPECIFIC THERAPY

Favorite
PT-007
APPLICATION OF MACHINE LEARNING COMBINED WITH POPPK AND QSP MODELS FOR ADVERSE EVENTS RISK PREDICTION OF A CD19-TARGETING BISPECIFIC THERAPY

Favorite
CT-006
APPLICATION OF PBPK TO ASSESS THE IMPACT OF UGT1A1 GENOTYPE ON DOLUTEGRAVIR EXPOSURE IN PREGNANT WOMEN AND FETUSES

Favorite
PII-161
APPLICATION OF PBPK TO ASSESS THE IMPACT OF UGT1A1 GENOTYPE ON DOLUTEGRAVIR EXPOSURE IN PREGNANT WOMEN AND FETUSES

Favorite
PII-162
APPLICATION OF PBPK TO SUPPLEMENT CLINICAL DATA AND INVESTIGATE THE IMPACT OF UGT1A1 PHENOTYPE ON DOLUTEGRAVIR EXPOSURE IN AFRICAN BREASTFED INFANTS

Favorite
CT-007
APPLICATION OF PBPK TO SUPPLEMENT CLINICAL DATA AND INVESTIGATE THE IMPACT OF UGT1A1 PHENOTYPE ON DOLUTEGRAVIR EXPOSURE IN AFRICAN BREASTFED INFANTS

Favorite
PII-163
APPLICATION OF PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING TO SUPPORT BIOEQUIVALENCE EVALUATION OF MESALAMINE DELAYED RELEASE TABLETS

Favorite
PII-001
APPROVED THERAPEUTIC PROTEINS WITH CHALLENGES IN CLINICAL ENDPOINTS EVALUATION WHERE PHARMACODYNAMIC BIOMARKERS MAY IMPROVE EFFICIENCY OF BIOSIMILAR DEVELOPMENT

Favorite
LB-006
ARTERIAL STIFFNESS AND SYSTEMIC VASCULAR CORRELATES OF BRAIN AMYLOIDOSIS AND PRECLINICAL AD

Favorite
PII-025
ASCENDING DOSE IN VIVO QT STUDIES HAVE THE SENSITIVITY TO DETECT QT INTERVAL CHANGES THAT ARE SUFFICIENT TO SUPPORT A CLINICAL QT WAIVER: ASSESSMENT OF QT/QTC INTERVAL CHANGES USING AN ESCALATING DOSE DESIGN IN TELEMETERED BEAGLE DOGS.

Favorite
PII-164
ASSESSING CYTOCHROME P450 DRUG INTERACTION RISK FOR ONC201 USING PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING

Favorite
LB-007
ASSESSING POTENTIAL DRUG-DRUG INTERACTIONS INVOLVING Δ-9-TETRAHYDROCANNABINOL AND CANNABIDIOL IN HEALTHY ADULTS USING PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELS

Favorite
PII-187
ASSESSMENT OF MALE INFERTILITY RISKS TO SUPPORT PRODUCT-SPECIFIC GUIDANCE DEVELOPMENT FOR GENERIC ORAL PRODUCTS.

Favorite
PII-165
AUTOMATED QUALIFICATION FRAMEWORK FOR PHYSIOLOGICALLY-BASED QUANTITATIVE SYSTEMS PHARMACOLOGY MODELING

Favorite
PII-099
AUTOSOMAL DOMINANT TUBULOINTERSTITIAL KIDNEY DISEASE: JOINT LONGITUDINAL-SURVIVAL DISEASE PROGRESSION MODELS.

Favorite
B
PII-074
BIPOLAR DISORDER GWAS IDENTIFIED A SNP SIGNAL IN THE THSD7A GENE THAT IS ASSOCIATED WITH RESPONSE TO VALPROATE AND LAMOTRIGINE.

Favorite
PII-100
BOSUTINIB MODEL-INFORMED PEDIATRIC DOSE RECOMMENDATIONS FOR LABEL SIMPLIFICATION

Favorite
PII-223
BRAIN MEASUREMENTS, PERIPHERAL BIOMARKERS, OR BOTH? IMPROVED PREDICTIONS OF RESPONSE TO SERTRALINE THROUGH MULTI-MODAL DATA INTEGRATION.

Favorite
AI-003
BRAIN MEASUREMENTS, PERIPHERAL BIOMARKERS, OR BOTH? IMPROVED PREDICTIONS OF RESPONSE TO SERTRALINE THROUGH MULTI-MODAL DATA INTEGRATION.

Favorite
LB-008
BRILAROXAZINE EFFICACY AND SAFETY IN THE PHASE 3 RECOVER TRIAL IN ACUTE SCHIZOPHRENIA

Favorite
C
PT-026
CAN MODEL BASED APPROACHES ACCURATELY IDENTIFY BIO(IN)EQUIVALENCE OF TOPICAL CLOTRIMAZOLE PRODUCTS?

Favorite
LB-009
CANNABIDIOL INCREASES EXPOSURE OF TACROLIMUS IN HEALTHY VOLUNTEERS.

Favorite
OAII-004
CARE TEAM ATTRIBUTES PREDICT LIKELIHOOD OF UTILIZING PHARMACOGENOMIC INFORMATION.

Favorite
PT-013
CARE TEAM ATTRIBUTES PREDICT LIKELIHOOD OF UTILIZING PHARMACOGENOMIC INFORMATION.

Favorite
PII-016
CELLULAR KINETICS OF ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, LISOCABTAGENE MARALEUCEL (LISO-CEL) AND ITS ASSOCIATION WITH EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)

Favorite
OAI-001
CHANGES IN QTC ACROSS DIFFERENT TRIMESTERS OF PREGNANCY AND PRE-ECLAMPSIA: A SYSTEMATIC REVIEW AND META-ANALYSIS

Favorite
PII-007
CHANGES IN QTC ACROSS DIFFERENT TRIMESTERS OF PREGNANCY AND PRE-ECLAMPSIA: A SYSTEMATIC REVIEW AND META-ANALYSIS

Favorite
TIP-004
CHARACTERIZATION OF LABETALOL IN PREGNANCY (THE CLIP STUDY).

Favorite
PII-017
CHARACTERIZING CELLULAR KINETICS OF IDECABTAGENE VICLEUCEL IN PATIENTS WITH TRIPLE-CLASS-EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA.

Favorite
PII-101
CHARACTERIZING EXPOSURE-RESPONSE RELATIONSHIPS OF IDECABTAGENE VICLEUCEL IN PATIENTS WITH TRIPLE-CLASS-EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA.

Favorite
PII-018
CLINICAL DOSE PREDICTION FOR CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELL THERAPIES USING A MULTI-SCALE QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) PLATFORM MODEL

Favorite
PII-102
CLINICAL DRUG-DRUG INTERACTION STUDY INTEGRATED WITH PBPK MODELLING PROVIDES INSIGHTS INTO THE INDUCTION POTENTIAL OF MAVACAMTEN ACROSS CYP2C19 PHENOTYPES.

Favorite
PII-197
CLINICAL EFFECTS OF MEDICAL CANNABIS FOR POST-TRAUMATIC STRESS DISORDER (PTSD) IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS - A RETROSPECTIVE COHORT STUDY BASED ON MINNESOTA'S MEDICAL CANNABIS REGISTRY.

Favorite
PII-049
CLINICAL PHARMACOKINETICS OF ABBV-400, A NOVEL C-MET-TARGETING ANTIBODY DRUG CONJUGATE, IN PATIENTS WITH ADVANCED SOLID TUMORS.

Favorite
PII-103
CLINICAL PHARMACOLOGY CHARACTERIZATION OF BLINATUMOMAB FROM SUBCUTANEOUS (SC) DOSING IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)

Favorite
PII-180
CLINICAL PHARMACOLOGY CONSIDERATIONS FOR FIRST-IN-HUMAN CLINICAL TRIALS FOR ENZYME REPLACEMENT THERAPY

Favorite
PII-198
CLINICAL PHARMACOLOGY CONSIDERATIONS IN EXTRAPOLATION OF EFFICACY AND SAFETY FROM ADULTS TO PEDIATRICS - LESSONS LEARNED FROM PEDIATRIC PROGRAMS OF DIRECT ORAL ANTICOAGULANTS.

Favorite
PII-050
CLINICAL PHARMACOLOGY OF IMETELSTAT, A FIRST-IN-CLASS OLIGONUCLEOTIDE TELOMERASE INHIBITOR

Favorite
PII-104
CLINICAL TRIAL SIMULATIONS FOR OPTIMAL SAMPLING TO ASSESS DURABILITY OF PCV IMMUNE RESPONSE IN ADULTS.

Favorite
PII-105
COMBINED PARENT AND PAYLOAD POPULATION PHARMACOKINETIC MODELING TO SUPPORT DOSE RECOMMENDATION OF THE NOVEL ANTI-TROP-2 ANTIBODY-DRUG CONJUGATE (ADC) SHR-A1921.

Favorite
PII-106
COMPARATIVE PHARMACOKINETICS AND SAFETY OF DWJ1451 AND CO-ADMINISTRATION OF OLMESARTAN MEDOXOMIL/AMLODIPINE/ROSUVASTATIN AND EZETIMIBE TABLETS IN HEALTHY KOREAN SUBJECTS

Favorite
CT-010
COMPARATIVE PHARMACOKINETICS AND SAFETY OF DWJ1451 AND CO-ADMINISTRATION OF OLMESARTAN MEDOXOMIL/AMLODIPINE/ROSUVASTATIN AND EZETIMIBE TABLETS IN HEALTHY KOREAN SUBJECTS

Favorite
PII-107
COMPARATIVE PHARMACOKINETICS/PHARMACODYNAMICS OF FIXED-DOSE COMBINATION OF RABEPRAZOLE/MAGNESIUM OXIDE 10/350MG (DHNP-2001A) TO THE CONVENTIONAL ENTERIC-COATED RABEPRAZOLE 10MG

Favorite
PII-026
COMPARISON OF CHANGES IN PUPIL DIAMETER AND HYPERCAPNIC VENTILATION FOR OXYCODONE AND PSYCHOTROPIC DRUGS ADMINISTERED ALONE OR IN COMBINATION

Favorite
PWI-001
COMPARISON OF METHODS OF FIRST-IN-HUMAN DOSE PREDICTION FOR ADENO-ASSOCIATED VIRUS-MEDIATED GENE THERAPIES IN FABRY DISEASE

Favorite
PII-019
COMPARISON OF METHODS OF FIRST-IN-HUMAN DOSE PREDICTION FOR ADENO-ASSOCIATED VIRUS-MEDIATED GENE THERAPIES IN FABRY DISEASE

Favorite
PT-022
COMPUTATIONAL SYSTEMS PHARMACOLOGY OF PYRROLOBENZODIAZEPINE-BASED ANTIBODY-DRUG CONJUGATES

Favorite
PII-008
C-PEPTIDE DISEASE PROGRESSION MODEL IN INDIVIDUALS WITH NEW-ONSET TYPE 1 DIABETES

Favorite
D
PII-009
DECIPHERING TYPE 1 DIABETES BY INTEGRATING ARTIFICIAL INTELLIGENCE WITH PANCREATIC WHOLE SLIDE IMAGING

Favorite
PII-188
DEEP DIVE INTO GENERIC DRUG APPLICATIONS TO SEEK DATA-DRIVEN HARMONIZATION OF BIOEQUIVALENCE CRITERIA FOR NARROW THERAPEUTIC INDEX DRUGS.

Favorite
LB-010
DEEP LEARNING PREDICTION OF VANCOMYCIN TIME-CONCENTRATION LEVELS IN NEONATES

Favorite
AI-006
DEEP LEARNING PREDICTION OF VANCOMYCIN TIME-CONCENTRATION LEVELS IN NEONATES

Favorite
PII-199
DESIGN AND MECHANICS OF FIVE MAJOR HUMAN MILK DRUG RESEARCH BIOBANKS: TIME TO CROSS BORDERS AND BARRIERS

Favorite
PII-108
DEVELOPING A PEDIATRIC ORAL SUSPENSION FORMULATION OF ABROCITINIB: A RELATIVE BIOAVAILABILITY AND PALATABILITY ASSESSMENT STUDY IN ADULTS

Favorite
PT-025
DEVELOPMENT AND VERIFICATION OF A NIFEDIPINE CONTROLLED RELEASE PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL IN PREGNANCY

Favorite
LB-011
DEVELOPMENT AND VERIFICATION OF MECHANISTIC PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODEL FOR ENZALUTAMIDE AND ITS N-DESMETHYL METABOLITE M2 AS INDUCERS OF CYP3A4

Favorite
PII-214
DEVELOPMENT OF A MECHANISTIC CK-PD MODEL TO QUANTITATIVELY CHARACTERIZE A CD19 DIRECTED CAR-T CELL THERAPY PRODUCT DEVELOPED USING RAPID MANUFACTURING

Favorite
PII-042
DEVELOPMENT OF A NOVEL FLUORESCENCE-BASED APPROACH FOR SOLUTE CARRIER-FOCUSED CRISPR/CAS9 KNOCKOUT SCREENING IN BREAST CANCER CELLS

Favorite
PII-166
DEVELOPMENT OF A PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL FOR BALOVAPTAN AND ITS MAJOR METABOLITE TO EVALUATE THEIR CYP3A4-MEDIATED VICTIM DRUG-DRUG INTERACTION (DDI) LIABILITY

Favorite
PII-167
DEVELOPMENT OF A PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL FOR VENLAFAXINE AND O-DESMETHYLVENLAFAXINE: ASSESSING THE IMPACT OF CYP2D6, CYP2C9 AND CYP2C19 GENETIC POLYMORPHISMS

Favorite
PT-016
DEVELOPMENT OF A QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) MODEL TO EVALUATE THE THERAPEUTIC POTENTIAL OF ANTI-CD19 CAR-T IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Favorite
PWII-004
DEVELOPMENT OF A QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) MODEL TO EVALUATE THE THERAPEUTIC POTENTIAL OF ANTI-CD19 CAR-T IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Favorite
PII-002
DEVELOPMENT OF A TRANSLATION PK-PD MODEL FOR IN VIVO CAR-T CELL THERAPIES USING CAR MRNA LOADED POLYMERIC NANOPARTICLE VECTOR

Favorite
PII-168
DEVELOPMENT OF GRAPHICAL INTERFACE IN R SHINY FOR PBPK MODEL-BASED PREDICTION AND SIMULATION OF DRUG DELIVERY IN THE FEMALE REPRODUCTIVE TRACT

Favorite
LB-012
DEVELOPMENT OF LC-MS/MS METHOD FOR THE SIMULTANEOUS DETERMINATION OF ANTI-NONTUBERCULOUS MYCOBACTERIA PULMONARY DISEASE DRUGS IN HUMAN PLASMA

Favorite
PT-021
DNA METHYLATION PATTERNS OF ARA-C, DAUNORUBICIN, AND ETOPOSIDE PHARMACOKINETIC/PHARMACODYNAMIC GENES ARE ASSOCIATED WITH THE CLINICAL OUTCOMES IN AML.

Favorite
PII-075
DNA METHYLTRANSFERASE INHIBITOR SYNERGIZE WITH IMMUNE CHECK POINT INHIBITORS IN THE TREATMENT OF TRIPLE NEGATIVE BREAST CANCER

Favorite
PII-109
DRUG-DRUG INTERACTION (DDI) STUDY OF THE PROTEOLYSIS TARGETING CHIMERA (PROTAC) ANDROGEN RECEPTOR (AR) DEGRADER BAVDEGALUTAMIDE IN COMBINATION WITH THE P-GLYCOPROTEIN (P-GP) SUBSTRATE FEXOFENADINE IN HEALTHY MALE VOLUNTEERS.

Favorite
PII-110
DRUG-DRUG INTERACTION EFFECT OF STEADY STATE LAZERTINIB EXPOSURE ON THE SINGLE-DOSE PHARMACOKINETICS OF MIDAZOLAM, ROSUVASTATIN AND METFORMIN.

Favorite
PII-111
DRUG-DRUG INTERACTION STUDY TO EVALUATE THE EFFECT OF STRONG CYP3A INHIBITION AND P450 INDUCTION ON THE PHARMACOKINETICS OF AFICAMTEN, AND THE EFFECT OF AFICAMTEN ON P-GLYCOPROTEIN, IN HEALTHY PARTICIPANTS.

Favorite
TIP-002
DRUG-GENE-NUTRACEUTICAL INTERACTIONS OF CANNABIDIOL AND TACROLIMUS.

Favorite
E
PII-112
EARLY MEROPENEM PHARMACOKINETICS AND TARGET ATTAINMENT IN CHILDREN WITH SEVERE VS NON-SEVERE SEPSIS

Favorite
PII-036
EFAVIRENZ AND DOLUTEGRAVIR MAY ALTER SIROLIMUS METABOLISM IN PEOPLE WITH HIV

Favorite
PII-200
EFFECT OF MODERATE HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF AFICAMTEN AND ITS METABOLITES.

Favorite
CT-002
EFFECT OF MODERATE HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF AFICAMTEN AND ITS METABOLITES.

Favorite
PT-023
EFFECT OF STEROID SPARING IMMUNOSUPPRESSIVE AGENTS USED IN THE TREATMENT OF IMMUNE RELATED ADVERSE EVENTS ON TUMOR OUTCOMES IN MELANOMA AND NON-SMALL CELL LUNG CANCER

Favorite
CT-008
EFFICACY AND SAFETY OF METFORMIN IN TYPE 2 DIABETIC PATIENTS WITH MILD HEPATIC IMPAIRMENTS: A RETROSPECTIVE COHORT STUDY USING PROPENSITY SCORE MATCHING METHOD.

Favorite
PII-201
EFFICACY AND SAFETY OF METFORMIN IN TYPE 2 DIABETIC PATIENTS WITH MILD HEPATIC IMPAIRMENTS: A RETROSPECTIVE COHORT STUDY USING PROPENSITY SCORE MATCHING METHOD.

Favorite
PII-051
ELRANATAMAB INTEGRATED EXPOSURE-RESPONSE (ER) EFFICACY AND SAFETY ANALYSES IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) USING A CLINICAL UTILITY INDEX (CUI)

Favorite
PT-019
ESTABLISHING A PARAMOUNT QUANTITATIVE FRAMEWORK LINKING DISEASE PROGRESSION AND CLINICAL OUTCOMES FOR PARKINSONS DISEASE

Favorite
PII-076
ESTIMATED PREVALENCE OF ACTIONABLE EXPOSURES TO PHARMACOGENETIC SUPPORTIVE CARE MEDICATIONS AMONG PATIENTS WITH GASTROINTESTINAL CANCERS.

Favorite
PII-052
ETHNIC SENSITIVITY ASSESSMENT OF MOSUNETUZUMAB PHARMACOKINETICS (PK) IN CHINESE PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL)

Favorite
CT-011
ETHNIC SENSITIVITY ASSESSMENT OF MOSUNETUZUMAB PHARMACOKINETICS (PK) IN CHINESE PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL)

Favorite
PII-077
EVALUATING THE ACCURACY OF PHARMACOGENOTYPE EXTRACTION FROM SOMATIC WHOLE EXOME SEQUENCING

Favorite
PII-215
EVALUATING THE EFFICACY OF COMBINATION OF CHECKPOINT INHIBITORS AND CHEMOTHERAPY IN LUNG CANCER USING A MECHANISTIC MODEL

Favorite
TIP-003
EVALUATING THE IMPACT OF XIAO-CHAI-HU-TANG ON PHARMACOKINETIC BEHAVIORS OF IRINOTECAN, RALOXIFENE AND THEIR METABOLITES IN HUMANS: A RUN-IN SAFETY STUDY.

Favorite
PT-015
EVALUATING THE UTILITY OF PROTEOMICS FOR IDENTIFICATION OF CIRCULATING PHARMACODYNAMIC BIOMARKERS FOR BIOSIMILARITY - USING PCSK-9 INHIBITOR BIOLOGICS AS A CASE STUDY

Favorite
PWII-002
EVALUATING THE UTILITY OF PROTEOMICS FOR IDENTIFICATION OF CIRCULATING PHARMACODYNAMIC BIOMARKERS FOR BIOSIMILARITY - USING PCSK-9 INHIBITOR BIOLOGICS AS A CASE STUDY

Favorite
PII-189
EVALUATION OF CARDIOVASCULAR TOXICITY PROFILE OF ALK INHIBITORS USING ADVERSE EVENT REPORTING DATABASE

Favorite
PII-003
EVALUATION OF DRUG-DRUG INTERACTION (DDI) POTENTIAL FOLLOWING EPCORITAMAB TREATMENT: RESULTS FROM EXPANSION OF A PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODEL.

Favorite
PII-078
EVALUATION OF G6PD ACTIVITY IN ALL OF US

Favorite
PII-114
EVALUATION OF HIGH-DOSE VUTIGLABRIDIN IN HEALTHY PARTICIPANTS: SAFETY, FOOD EFFECT, AND PHARMACOKINETICS AFTER SINGLE AND MULTIPLE ORAL ADMINISTRATIONS

Favorite
PII-053
EVALUATION OF IMPACT OF PRIOR CAR T THERAPY ON PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF ODRONEXTAMAB, A CD20×CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL).

Favorite
OAII-001
EVALUATION OF PHARMACOGENOMIC MEDICATION PRESCRIBING PATTERNS IN RURAL VERSUS URBAN SETTINGS.

Favorite
PT-004
EVALUATION OF PHARMACOGENOMIC MEDICATION PRESCRIBING PATTERNS IN RURAL VERSUS URBAN SETTINGS.

Favorite
PII-054
EVALUATION OF PHARMACOKINETICS (PK), SERUM CYTOKINES, AND SAFETY FOLLOWING INTRAVENOUS (IV) OR SUBCUTANEOUS (SC) STEP-UP DOSING OF UBAMATAMAB, A MUC16XCD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RECURRENT OVARIAN CANCER (OC)

Favorite
PII-010
EVALUATION OF PLASMA BIOMARKERS TO ASSESS THEIR ABILITY TO PREDICT CYP2D6 ACTIVITY IN INDIVIDUALS INCLUDING PATIENTS WITH TYPE 2 DIABETES.

Favorite
LB-013
EVALUATION OF SINGLE DOSE AND STEADY STATE PHARMACOKINETICS AND SAFETY OF AMX0035 IN CAUCASIAN AND JAPANESE HEALTHY MALE AND FEMALE PARTICIPANTS.

Favorite
PII-115
EVALUATION OF THE EFFECT OF VEPDEGESTRANT, A PROTEOLYSIS TARGETING CHIMERA (PROTAC) ESTROGEN RECEPTOR (ER) DEGRADER, ON ROSUVASTATIN PHARMACOKINETICS (PK) IN HEALTHY ADULT PARTICIPANTS.

Favorite
PII-169
EVALUATION OF THE POTENTIAL IMPACT ON PHAMACOKINETICS OF VARIOUS CYTOCHROME P450 SUBSTRATES OF INCREASING IL-6 LEVELS FOLLOWING ADMINISTRATION OF THE T-CELL BISPECIFIC ENGAGER GLOFITAMAB

Favorite
PII-020
EVIDENCE FOR INDUCIBLE CMV PROMOTER ACTIVITY IN HUMAN CHONDROCYTES

Favorite
PT-024
EVIDENCE SUPPORTING EFFICACY EXTRAPOLATIONS FOR TARGETED THERAPIES ACROSS MOLECULARLY DEFINED SUBSETS OF DISEASES IN THE ABSENCE OF SUBSET-SPECIFIC CLINICAL DATA.

Favorite
PWI-004
EVIDENCE SUPPORTING EFFICACY EXTRAPOLATIONS FOR TARGETED THERAPIES ACROSS MOLECULARLY DEFINED SUBSETS OF DISEASES IN THE ABSENCE OF SUBSET-SPECIFIC CLINICAL DATA.

Favorite
PII-033
EXPANDING THE USE OF REAL-WORLD DATA TO ANSWER CLINICAL PHARMACOLOGY QUESTIONS: DEVELOPMENT OF A USER-FRIENDLY DASHBOARD TO ASSESS PREVALENCE OF ORGAN IMPAIRMENT IN PATIENTS IN THE REAL-WORLD SETTING.

Favorite
PII-170
EXPOSURE OF VENLAFAXINE AND O-DESMETHYLVENLAFAXINE IN LACTATING MOTHERS AND THEIR INFANTS: INSIGHTS FROM A PBPK MODEL

Favorite
PII-021
EXPOSURE RESPONSE (E-R) RELATIONSHIPS OF LISOCABTAGENE MARALEUCEL (LISO-CEL) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL)

Favorite
PII-116
EXPOSURE RESPONSE (E-R) RELATIONSHIPS OF LISOCABTAGENE MARALEUCEL (LISO-CEL) MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)

Favorite
PII-117
EXPOSURE-RESPONSE OF TRASTUZUMAB DERUXTECAN (T-DXD) IN SUBJECTS WITH HER2-LOW METASTATIC BREAST CANCER

Favorite
LB-014
EXTRAPOLATING TRANSPORTER-MEDIATED DRUG-DRUG INTERACTION BETWEEN REMDESIVIR AND CLOFAZIMINE FROM IN VITRO TO IN VIVO: A STATIC APPROACH

Favorite
PII-118
EXTRAPOLATION APPROACH FOR UPADACITINIB IN JUVENILE IDIOPATHIC ARTHRITIS LEVERAGING PHARMACOKINETICS, EXPOSURE-RESPONSE, AND REAL-WORLD PATIENT DATA.

Favorite
F
PII-011
FC GAMMA RECEPTORS CONTRIBUTE TO CACHEXIA MEDIATED INCREASES IN MONOCLONAL ANTIBODY CLEARANCE

Favorite
PII-037
FIH STUDY OF INTRAVENOUS RECCE327: A NOVEL, BROAD SPECTRUM, SYNTHETIC ANTI-INFECTIVE

Favorite
PII-181
FLUOROQUINOLONES ATTRIBUTE AORTIC DISEASES THROUGH ENDOTHELIAL DYSFUNCTION.

Favorite
LB-015
FOOD AND CO-ADMINISTRATION OF ACID REDUCING AGENTS (ARAS) HAVE NO CLINICALLY SIGNIFICANT EFFECT ON THE PHARMACOKINETICS OF ETRUMADENANT - A POPULATION PHARMACOKINETIC (POPPK) AND PHYSIOLOGICALLY-BASED MODELING EXPLORATION.

Favorite
PII-027
FORMULATION IMPACT OF SSZ ON MTX EXPOSURE: A REPEAT DDI STUDY FOR A MK2 INHIBITOR BMS-986371

Favorite
G
PII-190
GLOBAL HARMONIZATION OF IMMEDIATE-RELEASE SOLID ORAL DRUG PRODUCT BIOEQUIVALENCE RECOMMENDATIONS AND THE IMPACT ON GENERIC DRUG DEVELOPMENT.

Favorite
H
PII-202
HIGHER CLEARANCE WHILE ON HIGH-DOSE CONTINUOUS DIALYSIS IS ASSOCIATED WITH DECREASED TARGET ATTAINMENT OF PIPERACILLIN IN A PATIENT POST-KIDNEY TRANSPLANT FOR PRIMARY HYPEROXALURIA.

Favorite
I
PII-171
IDENTIFY BIOPREDICTIVE DISSOLUTION FOR PREDICTING IN VIVO PERFORMANCE OF A BCS II DRUG PRODUCT UNDER FED CONDITION

Favorite
PII-079
IDENTIFYING EPIGENTIC INFLUENCES ON DRUG METABOLISM: MULTI-OMIC ANALYSES IN AFRICAN AMERICAN HEPATOCYTES

Favorite
PII-056
IMMUNOGENICITY AND SBMCA CHANGE IN THE COMPARISON OF TALQUETAMAB RECOMMENDED PHASE 2 DOSES

Favorite
PII-119
IMPACT OF CRUSHING OR GRINDING ON THE RELATIVE BIOAVAILABILITY OF THE VENETOCLAX TABLETS.

Favorite
PT-017
IMPACT OF CYP2D6 INHIBITORS ON PAIN CONTROL BY THE OPIOIDS

Favorite
PII-120
IMPACT OF MODERATE OR SEVERE HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF SOTORASIB AND ITS METABOLITES

Favorite
PII-121
IMPLEMENTATION OF QUANTITATIVE SYSTEMS PHARMACOLOGY MODELING IN TRANSLATION AND DOSE SELECTION FOR FIRST-IN-HUMAN PHASE 1/2 CLINICAL STUDY OF NTLA-2002 IN THE TREATMENT OF HEREDITARY ANGIOEDEMA

Favorite
LB-016
IMPROVED NONCOMPARTMENTAL HALF-LIFE ESTIMATION WITH TOBIT REGRESSION.

Favorite
PII-172
IN SILICO PREDICTION OF ION CHANNEL EFFECTS OF METHADONE LEADING TO QT INTERVAL PROLONGATION.

Favorite
PII-080
IN VITRO COMPARATIVE INHIBITORY PROFILES OF SEVERAL CYP2D6 INHIBITORS AND METABOLIC CAPABILITIES OF CYP2D6*1, CYP2D6*2, CYP2D6*10, AND CYP2D6*17 ON TRAMADOL METABOLISM

Favorite
PII-122
INCREASED DOSE CORRECTED AUC FOLLOWING SLOW SUBCUTANEOUS, INTRAMUSCULAR AND ORAL VERSUS INTRAVENOUS BOLUS HUMAN DRUG DOSING AND ITS POTENTIAL FOR INCREASED DOSE CORRECTED PHARMACODYNAMIC EFFECTS.

Favorite
PT-027
INHIBITION OF TACROLIMUS METABOLISM BY CANNABIDIOL AND ITS METABOLITES IN VITRO.

Favorite
PT-005
INTEGRATED GENOMICS AND TRANSCRIPTOMICS ANALYSES USING HAPMAP CELL LINES REVEAL NOVEL MODULATORS OF CELLULAR RESPONSE TO CYCLOPHOSPHAMIDE.

Favorite
PII-057
INTEGRATED PHARMACOKINETIC (PK)/PHARMACODYNAMIC MODELING OF PK, SAFETY, AND EFFICACY DATA TO SUPPORT DOSE OPTIMIZATION OF BMS-986158, A BROMODOMAIN AND EXTRA-TERMINAL INHIBITOR (BETI), IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF).

Favorite
E-001
INVESTIGATION OF THE RELATIONSHIP BETWEEN LEPR GENOTYPE-LEPTIN-GUT MICROBIOTA COMPOSITION IN HEALTHY NON-OBESE KOREAN ADULTS.

Favorite
K
PII-203
KLEBSIELLA PNEUMONIAE CONTRIBUTES TO REDUCE THIOPURINES CYTOTOXICITY IN VITRO: POSSIBLE IMPLICATIONS OF BACTERIAL METABOLISM

Favorite
PII-044
KNOWLEDGE, ATTITUDES, AND AWARENESS TOWARD MARIJUANA USE AT HISTORICALLY BLACK UNIVERSITY

Favorite
L
PII-012
LEVERAGING COPROPORPHYRIN-I AS AN ENDOGENOUS OATP1B BIOMARKER TO DISENTANGLE THE EFFECTS OF CEDIROGANT IN COMPLEX DRUG-DRUG INTERACTIONS.

Favorite
PII-173
LEVERAGING PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING AND CLINICAL DATA TO PREDICT DRUG-DRUG INTERACTIONS (DDI) OF AVAPRITINIB AND GUIDE DOSE ADJUSTMENTS.

Favorite
M
AI-007
MACHINE LEARNING MODELING TO PREDICT INFLIXIMAB PHARMACOKINETICS IN PEDIATRIC PATIENTS WITH CROHN'S DISEASE

Favorite
LB-017
MACHINE LEARNING MODELING TO PREDICT INFLIXIMAB PHARMACOKINETICS IN PEDIATRIC PATIENTS WITH CROHN'S DISEASE

Favorite
PII-209
MEDICAL SUPPLY TRANSPORT TO EVACUATION SHELTERS BY DRONE: PROPOSAL OF OITA MODEL USING RENDEZVOUS POINTS OF AIR AMBULANCE.

Favorite
PII-123
METABOLIC PROFILING OF ECOPIPAM

Favorite
PII-124
METABOLISM AND DISPOSITION OF [14C]-ONC201 (DORDAVIPRONE) IN HEALTHY ADULT PARTICIPANTS

Favorite
PII-125
MICRODOSING APPROACH TO EVALUATE WHETHER ECOPIPAM AFFECTS DRUG METABOLISM AND TRANSPORT OF CONCOMITANT MEDICATIONS

Favorite
PT-018
MINIMAL SAMPLING TO ASSESS MECHANISMS LINKING IMMUNE CHECKPOINT INHIBITOR PHARMACOKINETICS AND OUTCOMES IN CANCER PATIENTS

Favorite
PWII-003
MINIMAL SAMPLING TO ASSESS MECHANISMS LINKING IMMUNE CHECKPOINT INHIBITOR PHARMACOKINETICS AND OUTCOMES IN CANCER PATIENTS

Favorite
PII-081
MISS SCORES VARY IN ACCORDANCE WITH SLCO1B1 STATUS IN A COHORT OF JIA PATIENTS

Favorite
LB-018
MODEL BASED META ANALYSIS OF IMATINIB PHARMACOKINETICS: IN ABCB1, ABCG2, AND CYP3A5 GENOTYPES.

Favorite
PII-126
MODEL-BASED META-ANALYSIS (MBMA) OF OBJECTIVE RESPONSE RATE (ORR) AND GRADE 3+ TREATMENT-RELATED ADVERSE EVENTS (G3TRAE) IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC).

Favorite
PII-058
MODEL-BASED META-ANALYSIS (MBMA) OF OBJECTIVE RESPONSE RATE (ORR), PROGRESSION-FREE SURVIVAL (PFS), AND OVERALL SURVIVAL (OS) TO COMPARE PD-1 AND PD-L1 TREATMENT OUTCOMES IN METASTATIC (M) NON-SMALL-CELL LUNG CANCER (NSCLC)

Favorite
PWII-001
MODEL-BASED META-ANALYSIS (MBMA) OF OBJECTIVE RESPONSE RATE (ORR), PROGRESSION-FREE SURVIVAL (PFS), AND OVERALL SURVIVAL (OS) TO COMPARE PD-1 AND PD-L1 TREATMENT OUTCOMES IN METASTATIC (M) NON-SMALL-CELL LUNG CANCER (NSCLC)

Favorite
PII-004
MODEL-BASED REPRIMING WINDOW SELECTION FOR SUBCUTANEOUS EPCORITAMAB.

Favorite
LB-019
MODEL-INFORMED DOSE OPTIMIZATION FOR PROPHYLACTIC PIPERACILLIN-TAZOBACTAM IN PERIOPERATIVE PEDIATRIC PATIENTS.

Favorite
LB-020
MODEL-INFORMED DRUG DEVELOPMENT APPROACH FOR APPROVAL OF INTRAVENOUS FORMULATION OF SECUKINUMAB IN PSORIATIC ARTHRITIS (PSA), ANKYLOSING SPONDYLITIS (AS) AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA)

Favorite
E-002
MODEL-INFORMED PRECISION DOSING GUIDANCE OF ETHOSUXIMIDE DEVELOPED FROM A RANDOMIZED CONTROLLED CLINICAL TRIAL OF CHIILDHOOD ABSENCE EPILEPSY.

Favorite
PII-127
MODELING AND SIMULATION TO EXPLORE MECHANISMS OF PHARMACOKINETIC DRUG-DRUG INTERACTIONS OF ABEMACICLIB AND OLAPARIB IN PATIENTS WITH RECURRENT PLATINUM-RESISTANT OVARIAN CANCER

Favorite
PII-059
MODELING M-PROTEIN DYNAMICS IN SUBJECTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING VENETOCLAX: UTILITY OF EARLY M-PROTEIN MONITORING TO PREDICT PROGRESSION FREE SURVIVAL

Favorite
LB-021
MORPHINE-METABOLITE POPULATION PHARMACOKINETIC MODELING IN NEONATES WITH NEONATAL OPIOID WITHDRAWAL SYNDROME FOLLOWING ORAL ADMINISTRATION OF MORPHINE.

Favorite
LB-022
MULTIPLE ELIMINATION PATHWAYS ARE RESPONSIBLE FOR THE ELIMINATION OF ETRUMADENANT (ETRUMA) AFTER ORAL ADMINISTRATION OF [14C]-ETRUMA TO HUMANS.

Favorite
N
PII-204
NEUROLOGIC CONCERNS IN CRITICALLY ILL CHILDREN RECEIVING CEFEPIME

Favorite
PII-028
NO PHOTOTOXICITY OR PHOTOALLERGY EFFECT WITH MRX-5LBT (10%) LIDOCAINE PATCH ADMINISTRATION

Favorite
PII-128
NOVEL NONLINEAR POPULATION PHARMACOKINETIC MODEL OF IMETELSTAT, A FIRST-IN-CLASS OLIGONUCLEOTIDE TELOMERASE INHIBITOR

Favorite
O
PII-129
ONDANSETRON FOR THE TREATMENT OF NEONATAL OPIOID WITHDRAWAL SYNDROME.

Favorite
PII-013
OPTIMIZATION OF PARKINSON'S DISEASE DIGITAL BIOMARKERS THROUGH CLINICAL TRIAL SIMULATIONS.

Favorite
PT-028
ORAL PROGESTERONE-MEDIATED ATTENUATION OF IBUTILIDE-INDUCED QT INTERVAL LENGTHENING IN PREMENOPAUSAL AND POSTMENOPAUSAL WOMEN: POPULATION PHARMACOKINETIC/ PHARMACODYNAMIC MODEL

Favorite
OAI-004
ORAL PROGESTERONE-MEDIATED ATTENUATION OF IBUTILIDE-INDUCED QT INTERVAL LENGTHENING IN PREMENOPAUSAL AND POSTMENOPAUSAL WOMEN: POPULATION PHARMACOKINETIC/ PHARMACODYNAMIC MODEL

Favorite
P
LB-023
PATH TO REGULATORY REVIEW OF A QUANTITATIVE SYSTEM PHARMACOLOGY (QSP) MODEL

Favorite
PII-191
PEDIATRIC CLINICAL TRIAL DESIGNS FOR TESTOSTERONE REPLACEMENT THERAPY.

Favorite
PII-082
PERSPECTIVES ABOUT THE DEVELOPMENT AND IMPLEMENTATION OF PHARMACOGENOMIC CLINICAL DECISION SUPPORT TOOLS IN RURAL AND UNDERSERVED COMMUNITIES

Favorite
PII-205
PERSPECTIVES ON PHARMACOGENETIC-GUIDED TOBACCO CESSATION IN AN AMERICAN INDIAN POPULATION

Favorite
CT-003
PERSPECTIVES ON PHARMACOGENETIC-GUIDED TOBACCO CESSATION IN AN AMERICAN INDIAN POPULATION

Favorite
PII-083
PHARMACOGENOMIC ANALYSIS OF THE PHARMACOKINETIC ENDPOINTS FROM A DRUG-DRUG INTERACTION STUDY OF ENCORAFENIB IN COMBINATION WITH BINIMETINIB USING THE INJE COCKTAIL IN CANCER PATIENTS.

Favorite
PII-084
PHARMACOGENOMICS OF DILATED CARDIOMYOPATHY: A GENETIC DETERMINANT OF MYOCARDIAL RECOVERY

Favorite
PII-029
PHARMACOKINETIC EVALUATION OF GB1211 IN A NOVEL TABLET FORMULATION, ADMINISTERED UNDER FASTED AND FED CONDITIONS, AND COMPARED TO GB1211 CAPSULES, IN HEALTHY VOLUNTEERS

Favorite
AI-008
PHARMACOKINETIC MODEL-GUIDED ENOXAPARIN DOSING IN THE NICU: RETROSPECTIVE ANALYSIS TO PLAN FOR PROSPECTIVE FEASIBILITY TRIAL.

Favorite
LB-024
PHARMACOKINETIC MODEL-GUIDED ENOXAPARIN DOSING IN THE NICU: RETROSPECTIVE ANALYSIS TO PLAN FOR PROSPECTIVE FEASIBILITY TRIAL.

Favorite
PII-131
PHARMACOKINETIC PARAMETER ESTIMATION OF GENTAMICIN IN AN OBESE HEMODIALYSIS PATIENT: A CASE REPORT

Favorite
LB-025
PHARMACOKINETICALLY-GUIDED DOSING OF ORAL SORAFENIB IN PATIENTS WITH PEDIATRIC HEPATOCELLULAR CARCINOMA

Favorite
PII-060
PHARMACOKINETICS (PK) AND SOLUBLE MET (SMET) PHARMACODYNAMICS (PD) OF REGN5093, A MET X MET BISPECIFIC ANTIBODY, IN PATIENTS (PTS) WITH MET-ALTERED ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC)

Favorite
PII-061
PHARMACOKINETICS (PK) OF MIRZOTAMAB CLEZUTOCLAX (MIRZO-C) IN PATIENTS WITH RELAPSED AND REFRACTORY SOLID TUMORS: FIRST IN HUMAN STUDY RESULTS

Favorite
PII-132
PHARMACOKINETICS AND SAFETY OF MAVACAMTEN IN HEALTHY CHINESE SUBJECTS WITH DIFFERENT CYP2C19 PHENOTYPES

Favorite
CT-012
PHARMACOKINETICS OF BT8009, A BICYCLE TOXIN CONJUGATE (BTC), IN PATIENTS WITH SOLID TUMOR MALIGNANCIES AND VARIOUS DEGREES OF RENAL FUNCTIONS

Favorite
PII-062
PHARMACOKINETICS OF BT8009, A BICYCLE TOXIN CONJUGATE (BTC), IN PATIENTS WITH SOLID TUMOR MALIGNANCIES AND VARIOUS DEGREES OF RENAL FUNCTIONS

Favorite
PII-133
PHARMACOKINETICS OF EDARAVONE - COMPARISON OF EXPOSURE BETWEEN JAPANESE AND NON-JAPANESE BY POPULATION PHARMACOKINETIC ANALYSIS.

Favorite
PII-134
PHARMACOKINETICS OF INFIGRATINIB AND ITS ACTIVE METABOLITES IN PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC GASTRIC CANCER OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA HARBORING FGFR2 GENE AMPLIFICATION

Favorite
PII-135
PHARMACOKINETICS OF MONOCLONAL ANTIBODIES THROUGHOUT PREGNANCY: A SYSTEMATIC LITERATURE REVIEW

Favorite
PII-063
PHARMACOKINETICS OF TARLATAMAB, A DELTA LIKE LIGAND-3 (DLL3) TARGETED HALF-LIFE EXTENDED BISPECIFIC T-CELL ENGAGER (BITE) IMMUNOTHERAPY IN ADULT PATIENTS WITH PREVIOUSLY TREATED SMALL CELL LUNG CANCER (SCLC)

Favorite
PII-136
PHARMACOKINETICS OF TRASTUZUMAB DERUXTECAN (T-DXD) IN SUBJECTS WITH HER2-LOW METASTATIC BREAST CANCER

Favorite
PII-137
PHARMACOKINETICS, SAFETY AND TOLERABILITY OF ABBV-552 IN HEALTHY ADULT JAPANESE AND HAN CHINESE SUBJECTS

Favorite
PII-139
PHARMACOMETRICS-BASED APPROACH TO FIRST-IN-HUMAN INTRAVENOUS DOSE DETERMINATION FOR SRP-6004 IN PATIENTS WITH LIMB GIRDLE MUSCULAR DYSTROPHY 2B

Favorite
PII-140
PHARMCOKINETIC AND PHARMACODYNAMIC RELATIONSHIPS OF INTRANASALLY ADMINISTERED AND INTRAMUSCULARLY INJECTED EPINEPHRINE

Favorite
PII-030
PHASE 1 EVALUATION OF THE SAFETY, TOLERABILITY AND PLASMA AND CEREBROSPINAL FLUID PHARMACOKINETICS OF THE ADENOSINE A1R/A3R AGONIST AST-004 AFTER INTRAVENOUS INFUSION IN HEALTHY VOLUNTEERS

Favorite
PT-014
PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL OF DRUG DELIVERY IN THE FEMALE REPRODUCTIVE TRACT

Favorite
PII-174
PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL TO ASSESS THE IMPACT OF GENETIC VARIABILITY IN PATIENTS RECEIVING DEXMEDETOMIDINE.

Favorite
PT-011
PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING WITH PAIRED PLASMA AND CEREBROSPINAL FLUID CONCENTRATIONS OF LEVETIRACETAM IN PATIENTS WITH EXTERNAL VENTRICULAR DRAINS.

Favorite
PII-175
PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL FOR PANTOPRAZOLE IN CHILDREN WITH OBESITY.

Favorite
PII-176
PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING FOR ASSESSMENT OF THE DRUG-DRUG INTERACTION POTENTIAL OF ZAVEGEPANT

Favorite
PII-206
PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING FOR PREGNANCY.

Favorite
LB-026
PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING FOR THE PREDICTION OF BCRP-MEDIATED DRUG INTERACTIONS USING R STATISTICAL SOFTWARE

Favorite
PII-177
PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING TO EVALUATE THE GASTRIC ACID MODIFIER EFFECT ON RIMEGEPANT EXPOSURE

Favorite
LB-027
PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING TO PREDICT HUMAN DOSE OF MITHRAMYCIN ANALOGUE FOR THE TREATMENT OF EWING SARCOMA

Favorite
LB-028
PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING TO SUPPORT PEDIATRIC DOSING OF OLVEREMBATINIB IN CHILDREN WITH RELAPSED OR REFRACTORY PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA

Favorite
PII-141
PILOT FEASIBILITY STUDY OF AN ORAL CYP3A4/2C19 PROBE COCKTAIL TO PREDICT BORTEZOMIB CLEARANCE IN MULTIPLE MYELOMA PATIENTS

Favorite
CT-004
PIPERACILIN PHARMACOKINETICS AND TARGET ATTAINMENT IN PEDIATRIC LIVER TRANSPLANT RECIPIENTS.

Favorite
PII-207
PIPERACILIN PHARMACOKINETICS AND TARGET ATTAINMENT IN PEDIATRIC LIVER TRANSPLANT RECIPIENTS.

Favorite
PII-038
PK/PD OF RIFAMPICIN, ISONIAZID, PYRAZINAMIDE, AND ETHAMBUTOL IN MACROPHAGES INFECTED WITH M. TUBERCULOSIS.

Favorite
PII-039
PLERIXAFOR AS PATHOGEN AGNOSTIC PROPHYLAXIS OR ADVUVANT TREATMENT

Favorite
PII-142
POPULATION EXPOSURE–RESPONSE ANALYSIS SUPPORTS EFFICACY OUTCOMES OF GARADACIMAB IN PATIENTS WITH HEREDITARY ANGIOEDEMA.

Favorite
PII-143
POPULATION PHARMACOKINETIC (PK) MODEL OF AB521, A SMALL MOLECULE INHIBITOR OF HIF-2α, IN HEALTHY PARTICIPANTS.

Favorite
PII-144
POPULATION PHARMACOKINETIC AND PHARMACODYNAMIC MODELING OF NGM707, AN ILT2/ILT4 DUAL ANTAGONIST ANTIBODY IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS.

Favorite
PII-064
POPULATION PHARMACOKINETIC MODEL FOR THE TGFβR1 INHIBITOR PF-06952229 IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS

Favorite
PII-145
POPULATION PHARMACOKINETIC MODELING OF ALNUCTAMAB, A BCMA-BINDING T CELL ENGAGER, TO CHARACTERIZE THE BIOAVAILABILITY AND PHARMACOKINETICS IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

Favorite
PII-146
POPULATION PHARMACOKINETIC MODELING OF CAMRELIZUMAB IN PATIENTS WITH VARIOUS CANCER TYPES, INCLUDING ADVANCED HEPATOCELLULAR CARCINOMA.

Favorite
PII-147
POPULATION PHARMACOKINETIC MODELING OF NGM438 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS.

Favorite
PII-148
POPULATION PHARMACOKINETIC MODELING OF RIVOCERANIB IN HEALTHY SUBJECTS AND PATIENTS WITH VARIOUS CANCER TYPES, INCLUDING ADVANCED HEPATOCELLULAR CARCINOMA (HCC).

Favorite
LB-029
POPULATION PHARMACOKINETICS (PK) AND PHARMACODYNAMIC (PD) ANALYSES OF MULTIPLE INTRAVENOUS INFUSIONS OF NX210C PEPTIDE IN HEALTHY ELDERLY VOLUNTEERS (HEVS)

Favorite
PII-182
POPULATION PHARMACOKINETICS (PK) AND PK/PHARMACODYNAMICS ANALYSES TO REFINE PHASE 3 DOSE OF SETRUSUMAB IN PEDIATRIC PATIENTS WITH OSTEOGENESIS IMPERFECTA: RESULTS FROM PHASE 2 OF THE ORBIT STUDY

Favorite
PII-065
POPULATION PHARMACOKINETICS (POPPK) OF ABBV-383, A B-CELL MATURATION ANTIGEN (BCMA) × CD3 BISPECIFIC T-CELL-REDIRECTING ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM).

Favorite
PII-066
POPULATION PHARMACOKINETICS AND EXPOSURE-RESPONSE ANALYSES OF ZOLBETUXIMAB IN PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Favorite
PII-183
POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF PF-07265803 AND ITS METABOLITE IN PATIENTS WITH LAMIN A/C RELATED DILATED CARDIOMYOPATHY.

Favorite
PII-149
POPULATION PHARMACOKINETICS AND TUMOR GROWTH INHIBITION MODELING OF AN ANTI-CLAUDIN 18.2 ADC TO SUPPORT DRUG DEVELOPMENT DECISION-MAKING

Favorite
LB-030
POPULATION PHARMACOKINETICS MODEL OF PYRAZINAMIDE TO OPTIMIZE TUBERCULOSIS TREATMENT: AN INTERETHNIC COHORT STUDY OF DIABETES MELLITUS EFFECT ON DRUG EXPOSURE.

Favorite
LB-031
POPULATION PHARMACOKINETICS OF BORTEZOMIB: MODEL-BASED META-ANALYSIS

Favorite
PII-150
POPULATION PHARMACOKINETICS OF ENROFLOXACIN AND FLORFENICOL IN THE GIANT DANIO (DEVARIO AEQUIPINNATUS) FOLLOWING ORAL AND BATH ADMINISTRATION

Favorite
TIP-005
POPULATION PHARMACOKINETICS OF LEVOFLOXACIN IN KOREAN AND INDONESIAN TUBERCULOSIS PATIENTS: THE INFLUENCE OF RENAL FUNCTION AND DIABETES MELLITUS ON CLEARANCE.

Favorite
PII-067
POPULATION PHARMACOKINETICS OF ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA.

Favorite
PII-151
POPULATION PHARMACOKINETICS OF REZVILUTAMIDE (SHR3680) WITH TIME-VARYING AND SATURABLE RELATIVE BIOAVAILABLITY IN PROSTATE CANCER PATIENTS

Favorite
PT-002
POST-TRANSCRIPTIONAL GENE REGULATION AND ANTIDEPRESSANT TREATMENT RESPONSE: FUNCTIONAL CHARACTERIZATION OF ELAVL2 RNA-BINDING PROTEIN IN IPSC-DERIVED NEURONS.

Favorite
PII-085
POTENTIAL HEALTHCARE DISPARITIES AMONG PATIENTS WHO REGISTER FOR NOVEL PHARMACOGENETICS CONSULTATION SERVICE

Favorite
PII-152
PREDICT: A MACHINE LEARNING ALGORITHM FOR PREDICTING PHARMACOKINETIC PROFILES

Favorite
AI-005
PREDICTING REMISSION IN ACUTE BIPOLAR DEPRESSION: A MACHINE LEARNING STUDY WITH CROSS-TRIAL REPLICATION

Favorite
PT-009
PREDICTING REMISSION IN ACUTE BIPOLAR DEPRESSION: A MACHINE LEARNING STUDY WITH CROSS-TRIAL REPLICATION

Favorite
LB-032
PREDICTING THE POTENTIAL FOR CANNABIDIOL INDUCED DRUG-DRUG INTERACTIONS WITH MAJOR CYP450 ENZYMES USING MODEL-BASED APPROACHES

Favorite
PWII-005
PREDICTION OF OVERALL SURVIVAL IN MELANOMA PATIENTS: A TUMOR GROWTH INHIBITION OVERALL SURVIVAL MODELING FRAMEWORK

Favorite
PT-008
PREDICTION OF OVERALL SURVIVAL IN MELANOMA PATIENTS: A TUMOR GROWTH INHIBITION OVERALL SURVIVAL MODELING FRAMEWORK

Favorite
PII-153
PREDICTION OF PFS BASED ON TUMOR GROWTH INHIBITION METRICS IN HER2 POSITIVE BREAST CANCER PATIENTS FOLLOWING HER2 ADC FS-1502 TREATMENT

Favorite
PII-154
PREDICTIVE MODELING OF TACROLIMUS DOSE REQUIREMENTS AND TRANSPLANTATION OUTCOME IN LUNG TRANSPLANT RECIPIENTS ON SYSTEMIC AZOLE ANTIFUNGALS

Favorite
PII-224
PREDICTORS OF ALZHEIMER'S DISEASE AND RELATED DEMENTIA (ADRD) IN A HYPERTENSION (HTN) POPULATION WITHIN THE STATE OF FLORIDA USING ELECTRONIC HEALTH RECORD (EHR)-BASED DATA.

Favorite
PII-023
PREVALENCE, AGE AND SEX DISTRIBUTION OF PATIENTS WITH CHRONIC HEALTH CONDITIONS IN A LARGE HEALTHCARE SYSTEM

Favorite
CT-005
PREVALENCE, AGE AND SEX DISTRIBUTION OF PATIENTS WITH CHRONIC HEALTH CONDITIONS IN A LARGE HEALTHCARE SYSTEM

Favorite
PII-178
PROSPECTIVE APPLICATION OF PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING TO INFORM THE DESIGN OF A CLINICAL DRUG-DRUG INTERACTION (DDI) STUDY: CASE STUDY OF MEZIGDOMIDE

Favorite
Q
PII-218
QSP MODEL OF RHEUMATOID ARTHRITIS, CAPTURING RANGE OF RESPONSES TO METHOTREXATE, ADALIMUMAB AND TOCILIZUMAB THERAPIES

Favorite
PII-219
QUANTITATIVE CHARACTERIZATION OF ENHANCED TISSUE DISTRIBUTION AND INNATE KILLING POTENTIAL OF UN-ENGINEERED GAMMA DELTA Ɣδ T CELLS USING A MECHANISTIC MODEL

Favorite
R
PII-086
RACIAL DIFFERENCES IN THE ASSOCIATION BETWEEN UGT1A1*28 AND GENE EXPRESSION OF UGT1A1 AND SEARCHING FOR NOVEL REGULATORY VARIANTS OF UGT1A1.

Favorite
PII-068
REDUCED SYSTEMIC EXPOSURE TO A CAPECITABINE METABOLITE 5'-DFUR IN ABCC4 POLYMORPHISM MAY BE ASSOCIATED WITH INCREASES IN CAMP LEVEL AND SUBSEQUENT UPREGULATION OF THYMIDINE PHOSPHORYLASE

Favorite
PII-087
REDUCTION OF NEXT-GENERATION SEQUENCING FILE SIZE FOR EFFICIENT PHARMACOGENOTYPE EXTRACTION.

Favorite
PII-220
RESPONSE TO LYMPHOCYTE DEPLETING AND LYMPHOCYTE MODULATING THERAPIES IN DIFFERENT POPULATIONS OF PATIENTS WITH MULTIPLE SCLEROSIS INVESTIGATED BY QUANTITATIVE SYSTEMS PHARMACOLOGY MODEL

Favorite
PII-031
REVIEW OF TRANSLATIONAL CANCER RESEARCH TARGETING ADENOSINE RECEPTOR A2AR.

Favorite
PII-088
RISK DETERMINANTS FOR DRUG-INDUCED LIVER INJURY WITH COMMON ANTIBIOTICS IN THE ALL OF US RESEARCH PROGRAM

Favorite
S
PII-192
SAFETY CONSIDERATIONS OF SUBJECT POPULATION SELECTION IN BIOEQUIVALENCE STUDIES FOR GENERIC DRUG DEVELOPMENT.

Favorite
PII-155
SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE INTRAVENOUS ADMINISTRATIONS OF LENZILUMAB IN HEALTHY KOREAN SUBJECTS

Favorite
PII-024
STABILITY OF THE GUT MICROBIOME FROM HUMAN FECAL SAMPLES COLLECTED BY CONTACTLESS REGIONAL SHIPPING AND ITS APPLICATION IN CLINICAL TRIALS.

Favorite
PII-089
STEREOSELECTIVE METABOLISM OF TRIHEXYPHENIDYL: THE PATHWAY TO PRECISION DOSING

Favorite
PII-156
STRAIN- AND ROUTE-DEPENDENT PLASMA PHARMACOKINETICS AND BRAIN PENETRATION OF PACLITAXEL.

Favorite
T
PII-221
TETRAVALENCY IMPACT ON BISPECIFIC ANTIBODY-ACHIEVED RECEPTOR OCCUPANCY AND TARGET DOWNREGULATION: ESTIMATION BY TRANSLATIONAL PK/RO MODEL OF CTX8371 ANTIBODY

Favorite
PII-069
THE ANTI-OSTEOCLASTIC EFFECTS AND BONE-AFFINITY PROPERTIES OF GERANYLGERANYL DIPHOSPHATE SYNTHASE INHIBITOR RAM2061

Favorite
PII-193
THE CONTENTS OF IMMUNOGENICITY ASSESSMENT DURING THE REVIEW PROCESS OF NEW DRUG APPLICATION IN JAPAN

Favorite
PT-012
THE EFFECT OF BUPRENORPHINE VERSUS METHADONE TREATMENT ON NEUROCOGNITIVE IMPAIRMENT IN PERSONS WITH HIV AND OPIOID USE DISORDER.

Favorite
PII-157
THE EFFECT OF ITRACONAZOLE ON THE PHARMACOKINETICS (PK) OF VEPDEGESTRANT, A PROTEOLYSIS TARGETING CHIMERA (PROTAC) ESTROGEN RECEPTOR (ER) DEGRADER, IN HEALTHY ADULT PARTICIPANTS.

Favorite
PII-158
THE EFFECT OF VEPDEGESTRANT, A PROTEOLYSIS TARGETING CHIMERA (PROTAC) ESTROGEN RECEPTOR (ER) DEGRADER, ON DABIGATRAN PHARMACOKINETICS (PK) IN HEALTHY ADULT PARTICIPANTS.

Favorite
PII-034
THE FEASIBILITY OF PHARMACOKINETIC-GUIDED HYDROXYUREA DOSING FOR CHILDREN WITH SICKLE CELL ANEMIA IN UGANDA: ANALYSIS OF THE ALTERNATIVE DOSING AND PREVENTION OF TRANSFUSIONS (ADAPT) TRIAL.

Favorite
PII-040
THE IMPACT OF HIV-1 TAT AND MORPHINE ON SPATIAL DISTRIBUTION OF DRUGS IN THE BRAIN.

Favorite
PII-159
THE NEED FOR EQUITABLE REPRESENTATION IN PHARMACOKINETIC STUDIES TO ENHANCE OPTIMAL DOSING STRATEGIES TO TREAT POVERTY-RELATED DISEASES IN MALNOURISHED CHILDREN.

Favorite
LB-034
THE POPULATION PHARMACOKINETICS STUDY OF ANTI-TUMOR B AMONG HEALTHY VOLUNTEER AND ORAL CANCER PATIENTS TO INFORM DOSE DECISION

Favorite
PII-184
TOWARDS ASSISTING POTENTIAL PREVENTION CLINICAL TRIALS OF BONE-PROTECTIVE THERAPIES FOR DUCHENNE MUSCULAR DYSTROPHY USING DEEP SEGMENTED IMAGING BIOMARKER

Favorite
LB-035
TOWARDS MORE ROBUST EVALUATION OF THE PREDICTIVE PERFORMANCE OF PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELS: USING CONFIDENCE INTERVALS TO SUPPORT USE OF MODEL-INFORMED DOSING IN CLINICAL CARE

Favorite
PII-070
TUCATINIB DOES NOT INCREASE PACLITAXEL PLASMA CONCENTRATIONS IN PATIENTS WITH HER2+ GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Favorite
U
LB-036
UNDERSTANDING RELAXIN MECHANISMS OF ACTION THROUGH CARDIORENAL SYSTEMS PHARMACOLOGY MODELING

Favorite
OAI-003
UNDERSTANDING THE ASSOCIATIONS BETWEEN HIGH-DOSE METHOTREXATE PHARMACOKINETICS AND THE RISK OF TOXICITIES IN INFANTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA.

Favorite
PII-071
UNDERSTANDING THE ASSOCIATIONS BETWEEN HIGH-DOSE METHOTREXATE PHARMACOKINETICS AND THE RISK OF TOXICITIES IN INFANTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA.

Favorite
AI-004
UNLOCKING HIDDEN DRUG-REPURPOSING OPPORTUNITIES: NLP-POWERED TOPIC MODELING OF UNSTRUCTURED CURE-ID DATA

Favorite
PII-225
UNLOCKING HIDDEN DRUG-REPURPOSING OPPORTUNITIES: NLP-POWERED TOPIC MODELING OF UNSTRUCTURED CURE-ID DATA

Favorite
E-003
UNLOCKING THE DATA MYSTERY: A SIMULATION BASED DECISION GUIDE TO EVALUATE MISSING DATA IN BIOAVAILABILITY AND BIOEQUIVALENCE STUDIES.

Favorite
PII-014
UNRAVELING IL9 SERUM DISTRIBUTION PATTERNS: INSIGHTS FROM THE CYTOCON DATABASE

Favorite
PWI-003
USE OF QUANTITATIVE MAGNETIC RESONANCE IMAGING BIOMARKERS IN CLINICAL TRIALS FOR DUCHENNE MUSCULAR DYSTROPHY: MULTIVARIATE DISEASE PROGRESSION MODELS BRIDGING TIMED MOTOR FUNCTION TESTS AND FAT FRACTION

Favorite
PT-020
USE OF QUANTITATIVE MAGNETIC RESONANCE IMAGING BIOMARKERS IN CLINICAL TRIALS FOR DUCHENNE MUSCULAR DYSTROPHY: MULTIVARIATE DISEASE PROGRESSION MODELS BRIDGING TIMED MOTOR FUNCTION TESTS AND FAT FRACTION

Favorite
PII-015
UTILITY OF MIROMICS AND INTEGRATIVE MULTI-OMICS SYSTEMS ANALYSIS FOR IDENTIFICATION OF MIRNAS AS POTENTIAL PHARMACODYNAMIC BIOMARKERS OF IFNβ-1A BIOLOGICS

Favorite
OAI-002
UTILIZING A MINIMAL PHYSIOLOGICALLY-BASED PHARMACOKINETIC (MPBPK) MODEL FOR PREDICTING MATERNAL AND FETAL EXPOSURE TO MONOCLONAL ANTIBODIES DURING PREGNANCY

Favorite
PT-001
UTILIZING A MINIMAL PHYSIOLOGICALLY-BASED PHARMACOKINETIC (MPBPK) MODEL FOR PREDICTING MATERNAL AND FETAL EXPOSURE TO MONOCLONAL ANTIBODIES DURING PREGNANCY

Favorite
LB-037
UTILIZING MODEL BASED META-ANALYSIS TO CHARACTERIZE BREAKTHROUGH BLEEDING AND SPOTTING IN WOMEN USING HORMONAL CONTRACEPTIVES

Favorite
PII-208
UTILIZING STATISTICAL OR POPULATION PHARMACOKINETIC BASED MATCHING FOR VIRTUAL CONTROL GROUPS IN RENAL AND HEPATIC IMPAIRMENT STUDIES

Favorite
V
PII-222
VALIDATION OF A QUANTITATIVE SYSTEMS PHARMACOLOGY MODEL FOR CHRONIC HEPATITIS B.

Favorite
W
PII-032
WHAT TO EXPECT FROM A PHENYTOIN DRUG-DRUG INTERACTION STUDY: ADVERSE EVENT PROFILING AND SAFETY ASSESSMENT

Favorite

Designed by Cadmium |Technical Support
© Copyright 2025 Cadmium. All Rights Reserved.